Silexion Therapeutics (NASDAQ: SLXN) has reported promising preclinical data for SIL-204, its next-generation siRNA candidate targeting KRAS mutations in pancreatic cancer. This announcement comes just days after the company revealed strong results from its Phase 2 trial of LODER™, another RNAi-based therapy designed for pancreatic cancer treatment.
In the latest studies, SIL-204 demonstrated significant tumor reduction and necrosis in mouse models bearing the KRAS G12D mutation, a mutation commonly seen in about 70% of pancreatic cancer patients. The therapy utilizes an extended-release microparticle formulation, allowing a single administration to achieve the results previously seen only with daily injections.
New Hope for KRAS-Driven Cancers
Pancreatic cancer is notoriously difficult to treat, with limited therapeutic advancements in recent years. KRAS mutations, which drive the growth of many pancreatic tumors, have long presented a challenge for oncologists due to their resistance to standard treatments.
Silexion’s SIL-204 targets KRAS mutations using RNA interference (RNAi) technology, which works by silencing the gene responsible for producing cancer-promoting proteins. The company’s announcement highlights how SIL-204’s extended-release formulation has improved upon earlier siRNA technologies, showing effectiveness after just one dose in preclinical models.
The drug’s ability to induce necrosis in tumors is another positive sign, suggesting that SIL-204 could offer a more targeted, less invasive treatment option for pancreatic cancer patients. Silexion is planning to begin toxicology studies for SIL-204, with Phase 2/3 clinical trials expected to start in 2026.
Building on LODER™ Success
This announcement follows closely behind Silexion’s September 24 release of Phase 2 data for LODER™, a therapy aimed at improving surgical outcomes in non-resectable pancreatic cancer. The LODER™ trial showed a 56% objective response rate and a 67% improvement in tumor resectability. Together, these recent findings from LODER™ and SIL-204 position Silexion as a growing player in the precision oncology field.
Expansion to Colorectal Cancer
In addition to targeting pancreatic cancer, Silexion plans to test SIL-204 in other KRAS-driven cancers, beginning with colorectal cancer. The company has announced that preclinical studies in colorectal cancer models will begin soon, as SIL-204 could potentially be applied to a broader range of cancers with high KRAS mutation rates.
As Silexion advances both SIL-204 and LODER™, its focus on developing RNAi therapies for some of the hardest-to-treat cancers is gaining attention. With a robust pipeline and plans for further studies, the company is well-positioned to continue its momentum.
This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. The Author, Global Markets News Network, is a commercial digital brand compensated to provide coverage of news and developments of the company aforementioned as detailed in the full documentation and it is thus subject to conflicts of interest.